The changing landscape of cardiac metabolism

Journal of Molecular and Cellular Cardiology

Volumn 84, Issue , 2015, Pages 129-132

  Davogustto, Giovanni ^a   Taegtmeyer, Heinrich ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A; ADENOSINE TRIPHOSPHATE; DICHLOROACETIC ACID; PERHEXILINE; PYRUVATE DEHYDROGENASE COMPLEX; TRIMETAZIDINE;

CELL FUNCTION; DRUG EFFECT; DRUG MECHANISM; EDITORIAL; ENERGY CONSUMPTION; ENZYME ACTIVITY; EPIGENETICS; GLUCOSE OXIDATION; HEART MUSCLE CELL; HEART MUSCLE METABOLISM; HUMAN; INTRACELLULAR SIGNALING; METABOLIC REGULATION; NONHUMAN; PHARMACOLOGICAL STIMULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANIMAL; CYTOLOGY; FEMALE; HEART; IMMUNOLOGY; PATHOPHYSIOLOGY; REGENERATION; STEM CELL; STEM CELL TRANSPLANTATION; UTERUS;

ANIMALS; FEMALE; HEART; REGENERATION; STEM CELL TRANSPLANTATION; STEM CELLS; UTERUS;

EID: 84929501457     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.04.021     Document Type: Editorial

References (45)

1. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the epidemiology of diabetes interventions and complications (EDIC) study. JAMA 2003, 290:2159-2167.
2. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
3. Taegtmeyer H., Razeghi P. Heart disease in diabetes-resist the beginnings. J Am Coll Cardiol 2004, 43:315. [author reply].
4. Taegtmeyer H., Dilsizian V. Imaging myocardial metabolism and ischemic memory. Nat Clin Pract Cardiovasc Med 2008, 5(Suppl. 2):S42-S48.
5. Waddington C.H. Organizers and genes 1940, Cambridge University Press.
6. Ozanne S.E. Epigenetics and metabolism in 2014: metabolic programming-knowns, unknowns and possibilities. Nat Rev Endocrinol 2015, 11:67-68.
7. Goldberg A.D., Allis C.D., Bernstein E. Epigenetics: a landscape takes shape. Cell 2007, 128:635-638.
8. Matsuhashi T., Hishiki T., Zhou H., Ono T., Kaneda R., Iso T., et al. Activation of pyruvate dehydrogenase by dichloroacetate has the potential to induce epigenetic remodeling in the heart. J Mol Cell Cardiol 2015, 82:116-124. 10.1016/j.yjmcc.2015.02.021.
9. Taegtmeyer H. Energy metabolism of the heart: from basic concepts to clinical applications. Curr Probl Cardiol 1994, 19:59-113.
10. Taegtmeyer H., Golfman L., Sharma S., Razeghi P., van Arsdall M. Linking gene expression to function: metabolic flexibility in the normal and diseased heart. Ann N Y Acad Sci 2004, 1015:202-213.
11. Taegtmeyer H., Hems R., Krebs H.A. Utilization of energy-providing substrates in the isolated working rat heart. Biochem J 1980, 186:701-711.
12. Taegtmeyer H. Carbohydrate interconversions and energy production. Circulation 1985, 72:Iv1-Iv8.
13. Taegtmeyer H., Lubrano G. Rethinking cardiac metabolism: metabolic cycles to refuel and rebuild the failing heart. F1000Prime Rep 2014, 6:90.
14. Jaswal J.S., Keung W., Wang W., Ussher J.R., Lopaschuk G.D. Targeting fatty acid and carbohydrate oxidation-a novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta 1813, 2011:1333-1350.
15. Singh S., Schwarz K., Horowitz J., Frenneaux M. Cardiac energetic impairment in heart disease and the potential role of metabolic modulators: a review for clinicians. Circ Cardiovasc Genet 2014, 7:720-728.
16. Kankotia S., Stacpoole P.W. Dichloroacetate and cancer: new home for an orphan drug?. Biochim Biophys Acta 1846, 2014:617-629.
17. Stacpoole P.W. Lactic acidosis. Endocrinol Metab Clin North Am 1993, 22:221-245.
18. Stacpoole P.W., Moore G.W., Kornhauser D.M. Metabolic effects of dichloroacetate in patients with diabetes mellitus and hyperlipoproteinemia. N Engl J Med 1978, 298:526-530.
19. Stacpoole P.W., Wright E.C., Baumgartner T.G., Bersin R.M., Buchalter S., Curry S.H., et al. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. N Engl J Med 1992, 327:1564-1569.
20. Stacpoole P.W., Harman E.M., Curry S.H., Baumgartner T.G., Misbin R.I. Treatment of lactic acidosis with dichloroacetate. N Engl J Med 1983, 309:390-396.
21. McAllister A., Allison S.P., Randle P.J. Effects of dichloroacetate on the metabolism of glucose, pyruvate, acetate, 3-hydroxybutyrate and palmitate in rat diaphragm and heart muscle in vitro and on extraction of glucose, lactate, pyruvate and free fatty acids by dog heart in vivo. Biochem J 1973, 134:1067-1081.
22. Taniguchi M., Wilson C., Hunter C.A., Pehowich D.J., Clanachan A.S., Lopaschuk G.D. Dichloroacetate improves cardiac efficiency after ischemia independent of changes in mitochondrial proton leak. Am J Physiol Heart Circ Physiol 2001, 280:H1762-H1769.
23. Wargovich T.J., MacDonald R.G., Hill J.A., Feldman R.L., Stacpoole P.W., Pepine C.J. Myocardial metabolic and hemodynamic effects of dichloroacetate in coronary artery disease. Am J Cardiol 1988, 61:65-70.
24. Bersin R.M., Wolfe C., Kwasman M., Lau D., Klinski C., Tanaka K., et al. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 1994, 23:1617-1624.
25. Stacpoole P.W., Wright E.C., Baumgartner T.G., Bersin R.M., Buchalter S., Curry S.H., et al. Natural history and course of acquired lactic acidosis in adults. DCA-Lactic Acidosis Study Group. Am J Med 1994, 97:47-54.
26. Bonnet S., Archer S.L., Allalunis-Turner J., Haromy A., Beaulieu C., Thompson R., et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007, 11:37-51.
27. Lee L., Campbell R., Scheuermann-Freestone M., Taylor R., Gunaruwan P., Williams L., et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 2005, 112:3280-3288.
28. Horowitz J.D., Sia S.T., Macdonald P.S., Goble A.J., Louis W.J. Perhexiline maleate treatment for severe angina pectoris-correlations with pharmacokinetics. Int J Cardiol 1986, 13:219-229.
29. Gao D., Ning N., Niu X., Hao G., Meng Z. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart 2011, 97:278-286.
30. Zhang L., Lu Y., Jiang H., Zhang L., Sun A., Zou Y., et al. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol 2012, 59:913-922.
31. Holubarsch C.J., Rohrbach M., Karrasch M., Boehm E., Polonski L., Ponikowski P., et al. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin Sci (Lond) 2007, 113:205-212.
32. Home P.D., Pocock S.J., Beck-Nielsen H., Curtis P.S., Gomis R., Hanefeld M., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125-2135.
33. Young M.E., Laws F.A., Goodwin G.W., Taegtmeyer H. Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J Biol Chem 2001, 276:44390-44395.
34. Taegtmeyer H., Beauloye C., Harmancey R., Hue L. Insulin resistance protects the heart from fuel overload in dysregulated metabolic states. Am J Physiol Heart Circ Physiol 2013, 305:H1693-H1697.
35. Keating S.T., El-Osta A. Epigenetics and metabolism. Circ Res 2015, 116:715-736.
36. Kaelin W.G., McKnight S.L. Influence of metabolism on epigenetics and disease. Cell 2013, 153:56-69.
37. Sharma S., Guthrie P.H., Chan S.S., Haq S., Taegtmeyer H. Glucose phosphorylation is required for insulin-dependent mTOR signalling in the heart. Cardiovasc Res 2007, 76:71-80.
38. Sen S., Kundu B.K., Wu H.C., Hashmi S.S., Guthrie P., Locke L.W., et al. Glucose regulation of load-induced mTOR signaling and ER stress in mammalian heart. J Am Heart Assoc 2013, 2:e004796.
39. Young M.E., Yan J., Razeghi P., Cooksey R.C., Guthrie P.H., Stepkowski S.M., et al. Proposed regulation of gene expression by glucose in rodent heart. Gene Regul Syst Bio 2007, 1:251-262.
40. Wells L., Vosseller K., Hart G.W. Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science 2001, 291:2376-2378.
41. Taegtmeyer H., Sen S., Vela D. Return to the fetal gene program: a suggested metabolic link to gene expression in the heart. Ann N Y Acad Sci 2010, 1188:191-198.
42. Razeghi P., Young M.E., Cockrill T.C., Frazier O.H., Taegtmeyer H. Downregulation of myocardial myocyte enhancer factor 2C and myocyte enhancer factor 2C-regulated gene expression in diabetic patients with nonischemic heart failure. Circulation 2002, 106:407-411.
43. Lu C., Thompson C.B. Metabolic regulation of epigenetics. Cell Metab 2012, 16:9-17.
44. Cai L., Sutter B.M., Li B., Tu B.P. Acetyl-CoA induces cell growth and proliferation by promoting the acetylation of histones at growth genes. Mol Cell 2011, 42:426-437.
45. Yamane K., Indalao I.L., Chida J., Yamamoto Y., Hanawa M., Kido H. Diisopropylamine dichloroacetate, a novel pyruvate dehydrogenase kinase 4 inhibitor, as a potential therapeutic agent for metabolic disorders and multiorgan failure in severe influenza. PLoS One 2014, 9:e98032.